Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Goldschleger Eye Institute, Sheba Medical Center, Tel-Hashomer, Israel.
Graefes Arch Clin Exp Ophthalmol. 2023 Jan;261(1):233-240. doi: 10.1007/s00417-022-05864-7. Epub 2022 Oct 28.
The prevalence of myopia keeps increasing during the COVID-19 pandemic. We aimed to map the worldwide treatment preferences of ophthalmologists managing myopia control during the first wave of the pandemic.
An online questionnaire inquiring about pharmacological and optical treatment patterns during the first half of 2020 was sent to pediatric ophthalmology as well as general ophthalmology memberships worldwide. The results among pediatric ophthalmologists were compared to a previous study we performed before the pandemic.
A total of 2269 respondents from 94 countries were included. Most respondents were pediatric ophthalmologists (64.6%), followed by ophthalmologists from other subspecialties (32.3%). The preferred modality for all geographical regions was a combination therapy of pharmacological and optical treatments. When evaluated independently, the pharmacological treatment was more popular than the optical treatment in most regions other than East Asia (P < 0.001). Compared to a pre-pandemic questionnaire, the participation of pediatric ophthalmologists affiliated with non-university hospitals increased. Additionally, the prevalence of respondents utilizing either any type of pharmacological treatment and those that using only evidence-based treatments increased globally. Although a decline in the use of optical treatment was evident worldwide, the use of evidence-based optical treatments increased.
Ophthalmologists around the world preferred a combination therapy of pharmacological and optical treatments. More pediatric ophthalmologists treated myopia progression and preferred a better evidence-based approach to control myopia. These trends reflect a positive response and more awareness of the rising prevalence of myopia due to the increased burden of myopia imposed by the COVID-19 pandemic.
在 COVID-19 大流行期间,近视的患病率不断上升。我们旨在绘制全球眼科医生在大流行第一波期间管理近视控制的治疗偏好图。
向全球小儿眼科和普通眼科会员发送了一份关于 2020 年上半年药理学和光学治疗模式的在线问卷。小儿眼科医生的结果与我们在大流行前进行的先前研究进行了比较。
共纳入来自 94 个国家的 2269 名受访者。大多数受访者是小儿眼科医生(64.6%),其次是来自其他亚专科的眼科医生(32.3%)。所有地理区域首选的治疗方式都是药物治疗和光学治疗的联合疗法。在独立评估时,在东亚以外的大多数地区,药物治疗比光学治疗更受欢迎(P < 0.001)。与大流行前的问卷相比,来自非大学医院的小儿眼科医生的参与增加了。此外,全球使用任何类型的药物治疗和仅使用基于证据的治疗的受访者的比例均有所增加。尽管全世界光学治疗的使用明显下降,但基于证据的光学治疗的使用有所增加。
全世界的眼科医生都更喜欢药物治疗和光学治疗的联合疗法。更多的小儿眼科医生治疗近视进展,并倾向于采用更好的基于证据的方法来控制近视。这些趋势反映了由于 COVID-19 大流行对近视的负担增加导致近视患病率上升而产生的积极反应和更多的认识。